• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用新型 NF-κB/NFAT 报告细胞平台进行嵌合抗原受体文库筛选。

Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

机构信息

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.

出版信息

Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.

DOI:10.1016/j.ymthe.2018.11.015
PMID:30573301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6369451/
Abstract

Chimeric antigen receptor (CAR)-T cell immunotherapy is under intense preclinical and clinical investigation, and it involves a rapidly increasing portfolio of novel target antigens and CAR designs. We established a platform that enables rapid and high-throughput CAR-screening campaigns with reporter cells derived from the T cell lymphoma line Jurkat. Reporter cells were equipped with nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NFAT) reporter genes that generate a duplex output of enhanced CFP (ECFP) and EGFP, respectively. As a proof of concept, we modified reporter cells with CD19-specific and ROR1-specific CARs, and we detected high-level reporter signals that allowed distinguishing functional from non-functional CAR constructs. The reporter data were highly reproducible, and the time required for completing each testing campaign was substantially shorter with reporter cells (6 days) compared to primary CAR-T cells (21 days). We challenged the reporter platform to a large-scale screening campaign on a ROR1-CAR library, and we showed that reporter cells retrieved a functional CAR variant that was present with a frequency of only 6 in 1.05 × 10. The data illustrate the potential to implement this reporter platform into the preclinical development path of novel CAR-T cell products and to inform and accelerate the selection of lead CAR candidates for clinical translation.

摘要

嵌合抗原受体 (CAR)-T 细胞免疫疗法正在进行深入的临床前和临床研究,涉及到越来越多的新型靶抗原和 CAR 设计。我们建立了一个平台,该平台使用源自 T 细胞淋巴瘤系 Jurkat 的报告细胞,能够快速且高通量地进行 CAR 筛选实验。报告细胞配备了核因子 κB (NF-κB) 和活化 T 细胞核因子 (NFAT) 报告基因,分别产生增强型 CFP (ECFP) 和 EGFP 的双输出。作为概念验证,我们用 CD19 特异性和 ROR1 特异性 CAR 对报告细胞进行了修饰,并检测到高水平的报告信号,允许区分功能性和非功能性 CAR 构建体。报告数据高度可重现,与使用原代 CAR-T 细胞 (21 天) 相比,使用报告细胞完成每次测试实验的时间大大缩短 (6 天)。我们在 ROR1-CAR 文库中对报告平台进行了大规模筛选实验,并表明报告细胞检索到了一个功能型 CAR 变体,其频率仅为 1.05×10 的 6 次方。这些数据说明了将该报告平台应用于新型 CAR-T 细胞产品的临床前开发路径的潜力,并为临床转化的 CAR 候选物的选择提供信息和加速。

相似文献

1
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.利用新型 NF-κB/NFAT 报告细胞平台进行嵌合抗原受体文库筛选。
Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.
2
The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.嵌合抗原受体 T 细胞报告系统中靶向结合 PD-L1 阻断剂对表达 EGFR 肿瘤的西妥昔单抗效应。
Cancer Invest. 2021 Apr;39(4):285-296. doi: 10.1080/07357907.2021.1894570. Epub 2021 Mar 11.
3
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.诱导性局部递送抗 PD-1 scFv 增强了 ROR1 CAR-T 细胞在三阴性乳腺癌中的抗肿瘤活性。
Breast Cancer Res. 2022 Jun 3;24(1):39. doi: 10.1186/s13058-022-01531-1.
4
Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1.三参数T细胞报告基因系中协同刺激和共抑制的评估:NF-κB、NFAT和AP-1的同步测量。
J Immunol Methods. 2016 Mar;430:10-20. doi: 10.1016/j.jim.2016.01.007. Epub 2016 Jan 15.
5
NFAT and NF-κB dynamically co-regulate TCR and CAR signaling responses in human T cells.NFAT 和 NF-κB 在人类 T 细胞中动态协同调节 TCR 和 CAR 信号转导反应。
Cell Rep. 2023 Jul 25;42(7):112663. doi: 10.1016/j.celrep.2023.112663. Epub 2023 Jun 21.
6
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.受体亲和力和细胞外结构域修饰影响 ROR1 特异性嵌合抗原受体 T 细胞对肿瘤的识别。
Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.
7
Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.使用Jurkat报告T细胞系评估新型嵌合抗原受体的功能。
Front Mol Med. 2023 Feb 22;3:1070384. doi: 10.3389/fmmed.2023.1070384. eCollection 2023.
8
4-1BB enhancement of CAR T function requires NF-κB and TRAFs.4-1BB 增强 CAR T 功能需要 NF-κB 和 TRAFs。
JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.
9
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.复合 CD79A/CD40 共刺激内源性结构域增强了 CD19CAR-T 细胞的增殖和存活。
Mol Ther. 2021 Sep 1;29(9):2677-2690. doi: 10.1016/j.ymthe.2021.04.038. Epub 2021 May 1.
10
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.将靶向受体酪氨酸激酶样孤儿受体-1(ROR1)的嵌合抗原受体通过睡美人转座系统导入多种记忆性T细胞群体
PLoS One. 2015 Jun 1;10(6):e0128151. doi: 10.1371/journal.pone.0128151. eCollection 2015.

引用本文的文献

1
Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma.利用CARtein系统对BCMA和SLAMF7进行双重靶向:具有内含肽介导剪接的嵌合抗原受体引发针对多发性骨髓瘤的特异性T细胞活化。
Front Immunol. 2025 Jul 31;16:1613222. doi: 10.3389/fimmu.2025.1613222. eCollection 2025.
2
Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review.通过高通量筛选策略扩展用于CAR结构域探索的CAR工具库:全面综述
J Immunother Cancer. 2025 Apr 9;13(4):e010658. doi: 10.1136/jitc-2024-010658.
3
Effectors of the Future: Universal Chimeric Antigen Receptor.未来的效应器:通用嵌合抗原受体
Transfus Med Hemother. 2024 Jul 15;52(1):61-76. doi: 10.1159/000539609. eCollection 2025 Feb.
4
Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway.Cullin-5缺陷可能通过调节JAK/STAT信号通路促进嵌合抗原受体T细胞的效应功能。
Nat Commun. 2024 Dec 10;15(1):10376. doi: 10.1038/s41467-024-54794-x.
5
CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer.基于靶向人乳头瘤病毒16型E6的T细胞受体模拟纳米抗体的嵌合抗原受体T细胞对宫颈癌具有抗肿瘤活性。
Mol Ther Oncol. 2024 Oct 9;32(4):200892. doi: 10.1016/j.omton.2024.200892. eCollection 2024 Dec 19.
6
Challenges and future perspectives for high-throughput chimeric antigen receptor T cell discovery.高通量嵌合抗原受体 T 细胞发现的挑战和未来展望。
Curr Opin Biotechnol. 2024 Dec;90:103216. doi: 10.1016/j.copbio.2024.103216. Epub 2024 Oct 21.
7
Regulation of CAR transgene expression to design semiautonomous CAR-T.嵌合抗原受体(CAR)转基因表达的调控以设计半自主CAR-T细胞
Mol Ther Oncol. 2024 Jun 14;32(3):200833. doi: 10.1016/j.omton.2024.200833. eCollection 2024 Sep 19.
8
Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.使用Jurkat报告T细胞系评估新型嵌合抗原受体的功能。
Front Mol Med. 2023 Feb 22;3:1070384. doi: 10.3389/fmmed.2023.1070384. eCollection 2023.
9
Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness.共刺激CD28/CD40信号分子可增强嵌合抗原受体T细胞(CAR-T)的疗效和干性。
Mol Ther Oncol. 2024 Jun 18;32(3):200837. doi: 10.1016/j.omton.2024.200837. eCollection 2024 Sep 19.
10
Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB.通过CD2、CD28和4-1BB的信号结构域进行转录重编程。
iScience. 2024 Feb 19;27(3):109267. doi: 10.1016/j.isci.2024.109267. eCollection 2024 Mar 15.

本文引用的文献

1
4-1BB enhancement of CAR T function requires NF-κB and TRAFs.4-1BB 增强 CAR T 功能需要 NF-κB 和 TRAFs。
JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.
2
MORPHOFUNCTIONAL CHANGES OF JURKAT LINE T-LYMPHOBLASTS AT SHORT-TERM CONTACT WITH RELIEF CALCIUM PHOSPHATE SURFACE.Jurkat系T淋巴细胞与浮雕磷酸钙表面短期接触后的形态功能变化
Tsitologiia. 2016;58(10):778-84.
3
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.靶向 ROR1 膜近端表位的 T 细胞结合双特异性抗体的强效和选择性抗肿瘤活性。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5467-E5476. doi: 10.1073/pnas.1719905115. Epub 2018 May 29.
4
A genome-wide survey of mutations in the Jurkat cell line.Jurkat 细胞系基因突变的全基因组研究。
BMC Genomics. 2018 May 8;19(1):334. doi: 10.1186/s12864-018-4718-6.
5
A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies.一种基于Jurkat 76的三参数报告系统,用于评估T细胞受体功能和过继性T细胞策略。
Oncotarget. 2018 Apr 3;9(25):17608-17619. doi: 10.18632/oncotarget.24807.
6
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.PI3K 调控嵌合抗原受体修饰 T 细胞在体内的持久性。
Leukemia. 2018 May;32(5):1157-1167. doi: 10.1038/s41375-017-0008-6. Epub 2018 Feb 2.
7
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.通过 ICOS 和 4-1BB 共刺激增强 CAR T 细胞的持久性。
JCI Insight. 2018 Jan 11;3(1). doi: 10.1172/jci.insight.96976.
8
A cellular platform for the evaluation of immune checkpoint molecules.用于评估免疫检查点分子的细胞平台。
Oncotarget. 2017 May 4;8(39):64892-64906. doi: 10.18632/oncotarget.17615. eCollection 2017 Sep 12.
9
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.嵌合抗原受体中 4-1BB 共刺激会阻碍 T 细胞存活,且具有载体依赖性。
Cell Rep. 2017 Oct 3;21(1):17-26. doi: 10.1016/j.celrep.2017.09.015.
10
Phenotypic screening-the fast track to novel antibody discovery.表型筛选——发现新型抗体的快速通道。
Drug Discov Today Technol. 2017 Mar;23:83-90. doi: 10.1016/j.ddtec.2017.03.004. Epub 2017 Apr 25.